BioNTech (ADRs) Aktie
Mit dem Broker, der Top-Insights, geprüfte Analysen
und Trading ab 0 € vereint (zzgl. Spreads).
Kursziele der BioNTech (ADRs)-Aktie in USD
Diese Analysten bewerten die BioNTech (ADRs)-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| UBS AG | 125,00 USD | +43,33% | 04.11.2026 | |
| Jefferies & Company Inc. | 138,00 USD | +58,24% | 04.11.2026 | |
| JP Morgan Chase & Co. | 86,86 USD | -0,40% | 27.10.2026 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 140,00 USD | +60,53% | 07.10.2026 | |
| Goldman Sachs Group Inc. | 127,00 USD | +45,63% | 04.09.2026 | |
| Deutsche Bank AG | 140,00 USD | +60,53% | 26.08.2026 | |
| Bernstein Research | 96,00 USD | +10,08% | 04.08.2026 |
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| AstraZeneca PLC | 9 | 1 | 0 | 163,14 GBP | - |
| Bayer | 7 | 2 | 0 | 57,69 EUR | +1,21% |
| BioNTech (ADRs) | 5 | 2 | 0 | 121,84 USD | +39,71% |
| CanSino Biologics Inc. Registered Shs -A- | 0 | 0 | 0 | - | - |
| CureVac | 0 | 0 | 0 | - | - |
| Fresenius Medical Care (FMC) St. | 1 | 4 | 4 | 36,05 EUR | -11,92% |
| Fresenius SE & Co. KGaA | 8 | 1 | 0 | 54,96 EUR | +2,84% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| Inovio Pharmaceuticals Inc | 0 | 0 | 0 | - | - |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Moderna Inc | 0 | 1 | 0 | 45,00 USD | -82,06% |
| Novartis AG | 1 | 7 | 2 | 123,90 CHF | -7,87% |
| Novavax Inc. | 0 | 0 | 0 | - | - |
| Pfizer Inc. | 1 | 6 | 1 | 28,43 USD | -3,17% |
| Roche Holding AG Inhaber-Partizipationsschein | 4 | 4 | 1 | 383,44 CHF | -4,57% |
| Sanofi S.A. | 5 | 5 | 0 | 94,11 EUR | +8,77% |
| Shanghai Fosun Pharmaceutical (Group) Co Ltd (A) | 0 | 0 | 0 | - | - |
| Sinopharm Group Co Ltd (H) | 0 | 0 | 0 | - | - |
| Sinovac Biotech LtdShs | 0 | 0 | 0 | - | - |
| Valneva | 0 | 0 | 0 | - | - |